Allergy Service, Carlos Haya Hospital, Malaga, Spain.
J Allergy Clin Immunol. 2011 Dec;128(6):1192-7. doi: 10.1016/j.jaci.2011.06.012. Epub 2011 Jul 23.
Patients previously given a diagnosis of nonallergic rhinitis (NAR) might have a new form of local allergic rhinitis (LAR) with local production of specific IgE antibodies and a positive response to a nasal allergen provocation test (NAPT).
We evaluated an NAPT protocol using multiple aeroallergens (NAPT-M) for the detection of polysensitization to several aeroallergens in patients with LAR.
NAPT-Ms with 2 different panels of aeroallergens for patients with perennial and seasonal rhinitis were performed in 25 patients with LAR and 25 patients with NAR whose disease was diagnosed by means of NAPTs 1 year earlier. The response to nasal challenge was evaluated based on subjective (nasal-ocular symptoms) and objective (acoustic rhinometry) parameters. Nasal levels of tryptase and eosinophil cationic protein were determined by means of immunoassay at baseline, 15 minutes, and 1, 2, and 24 hours after challenge.
NAPT-Ms showed 100% concordance with the gold standard of NAPTs with a single aeroallergen. No false-positive or false-negative responses were detected. The use of NAPT-Ms achieved 75% reduction in the total number of visits required for final diagnosis in the NAR group (from 168 to 42 visits) and a 55% reduction in the LAR group (from 144 to 65 visits) compared with NAPTs with a single aeroallergen.
These results demonstrate that clinically relevant polysensitization to aeroallergens in patients with LAR occurred and that the NAPT-M is a useful, specific, sensitive, reproducible, and less time-consuming in vivo diagnostic test for the screening of patients with LAR.
先前被诊断为非变应性鼻炎(NAR)的患者可能患有新型局部变应性鼻炎(LAR),其具有局部产生特异性 IgE 抗体和对鼻变应原激发试验(NAPT)的阳性反应。
我们评估了一种使用多种气传过敏原的 NAPT 方案(NAPT-M),用于检测 LAR 患者对多种气传过敏原的多敏化。
对 25 例 LAR 患者和 25 例 NAR 患者进行了 NAPT-Ms,这些患者的疾病是通过 1 年前的 NAPTs 诊断的。根据主观(鼻-眼症状)和客观(声鼻测量)参数评估鼻挑战的反应。在基线、鼻挑战后 15 分钟、1 小时、2 小时和 24 小时,通过免疫测定法测定鼻组织中的类胰蛋白酶和嗜酸性粒细胞阳离子蛋白的水平。
NAPT-Ms 与单一气传过敏原的金标准 NAPTs 具有 100%的一致性,未检测到假阳性或假阴性反应。与单一气传过敏原的 NAPTs 相比,NAPT-Ms 在 NAR 组中最终诊断所需的总就诊次数减少了 75%(从 168 次减少到 42 次),在 LAR 组中减少了 55%(从 144 次减少到 65 次)。
这些结果表明,LAR 患者确实存在与临床相关的气传过敏原多敏化,并且 NAPT-M 是一种有用、特异性、敏感、可重复且耗时更少的 LAR 患者筛选的体内诊断试验。